﻿<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Cision News</title><link>https://news.cision.com</link><description>Cision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.</description><pubDate>Tue, 09 Jun 2026 08:49:05 GMT</pubDate><image><title>Cision News</title><width>146</width><height>60</height><link>https://news.cision.com</link><url>https://news.cision.com/Content/img/news-logo.png</url></image><item><title>Interim report, May–January 2021/22</title><link>https://news.cision.com/elekta/r/interim-report--may-january-2021-22,c3513327</link><guid isPermaLink="false">cision4193970</guid><description><![CDATA[Strong demand, and supply chain challenges

The demand for Elekta’s solutions continued to be strong in the third quarter, the fifth consecutive quarter with underlying order growth, resulting in Elekta’s strongest order backlog ever. However, the global supply chain challenges remained, and revenue and margins came in lower than last year. We are fully committed to returning to revenue growth and margin expansion.

Gustaf Salford
President and CEO
 

Third quarter

  · Gross order intake amounted to SEK 4,441 M (3,954), corresponding to an 8 percent increase in constant currency.]]></description><pubDate>Thu, 24 Feb 2022 06:30:00 GMT</pubDate></item><item><title>Elekta announces preliminary third quarter results</title><link>https://news.cision.com/elekta/r/elekta-announces-preliminary-third-quarter-results,c3506143</link><guid isPermaLink="false">cision4184436</guid><description><![CDATA[STOCKHOLM – Elekta (EKTA-B.ST) today published preliminary financial results for the third quarter 2021/22.

The demand for Elekta’s precision radiation medicine solutions continued to be strong in the quarter, driven by Europe and recovery in several emerging markets such as Egypt and India. Orders grew with 8 percent, the fifth consecutive quarter with underlying order growth, resulting in Elekta’s strongest order backlog ever.

Elekta has maintained its strong commitment to customers and their patients by continued focus on installing new devices and servicing the installed base. As]]></description><pubDate>Mon, 14 Feb 2022 12:30:00 GMT</pubDate></item><item><title>Invitation to the presentation of Elekta’s third quarter 2021/22</title><link>https://news.cision.com/elekta/r/invitation-to-the-presentation-of-elekta-s-third-quarter-2021-22,c3498659</link><guid isPermaLink="false">cision4175108</guid><description><![CDATA[SWEDEN, February 4, 2022 – Elekta (EKTA-B.ST) invites analysts and investors to a presentation of the third quarter 2021/22 at 10:00 a.m. CET on February 24. The interim report for the third quarter will be published at 7:30 a.m. CET on the same day.

The company’s development will be presented by Elekta’s President and CEO Gustaf Salford together with CFO Tobias Hägglöv. After the presentation, held in English, a Q&A session will follow.

The presentation will be broadcasted live on the web. It will be necessary to join the phone conference if you plan to ask questions. A recording of]]></description><pubDate>Fri, 04 Feb 2022 06:30:00 GMT</pubDate></item><item><title>Elekta increases customer focus with direct presence in Philippines</title><link>https://news.cision.com/elekta/r/elekta-increases-customer-focus-with-direct-presence-in-philippines,c3496900</link><guid isPermaLink="false">cision4172645</guid><description><![CDATA[New legal entity in the Philippines will enable Elekta to meet underserved access to the best cancer care
STOCKHOLM, February 2, 2022 – Elekta (EKTA-B.ST) announced today that it has established an office in the Philippines’ capital, Manila, to offer new and existing customers superior service, education and training opportunities and faster access to the latest cancer care solutions. A direct presence in the country will allow Elekta to better address the Philippines’ large gap in access to radiation therapy and the huge patient backlog, caused in part by the Covid pandemic.

Habib Nehme,]]></description><pubDate>Wed, 02 Feb 2022 06:30:00 GMT</pubDate></item><item><title>Elekta to appoint Tobias Hägglöv as Chief Financial Officer</title><link>https://news.cision.com/elekta/r/elekta-to-appoint-tobias-hagglov-as-chief-financial-officer,c3482446</link><guid isPermaLink="false">cision4154712</guid><description><![CDATA[STOCKHOLM, January 7, 2022 – Elekta (EKTA-B.ST) announced today that it will appoint Tobias Hägglöv as Chief Financial Officer effective February 1, 2022, taking over from Johan Adebäck. Tobias Hägglöv has previously held the role of CFO at Recipharm as well as senior management positions at LEAX, Electrolux, SAS and Accenture.

Gustaf Salford, CEO of Elekta, said: “I’m very pleased that Tobias will join Elekta. He brings strong expertise within finance and IT as well as broad experience from multinational companies. Elekta is fully focused on delivering on our ACCESS 2025 strategy and is]]></description><pubDate>Fri, 07 Jan 2022 06:30:00 GMT</pubDate></item><item><title>Elekta’s new sustainability-linked bond oversubscribed</title><link>https://news.cision.com/elekta/r/elekta-s-new-sustainability-linked-bond-oversubscribed,c3464534</link><guid isPermaLink="false">cision4132509</guid><description><![CDATA[Elekta AB (publ) has successfully issued the first sustainability-linked bonds in Sweden with a pure social KPI. The funds of SEK 1.5 billion are intended to contribute to increasing the global access of cancer care in underserved markets.
STOCKHOLM, December 3, 2021 – Elekta (EKTA-B.ST) announced today that it has issued SEK 1.5 billion senior unsecured sustainability-linked bonds under its Medium Term Note Program (MTN-Program). One of the bonds, in the amount of SEK 1,150 million, has a maturity of 5 years with a coupon of 3 months STIBOR plus 0.90 percent. The other bond, in the amount]]></description><pubDate>Fri, 03 Dec 2021 06:30:00 GMT</pubDate></item><item><title>More cancer patients in Africa to benefit from advanced radiation therapy with Elekta Unity MR-Linac</title><link>https://news.cision.com/elekta/r/more-cancer-patients-in-africa-to-benefit-from-advanced-radiation-therapy-with-elekta-unity-mr-linac,c3461491</link><guid isPermaLink="false">cision4125700</guid><description><![CDATA[Order also includes linear accelerators and brachytherapy equipment for precision radiation therapy at International Children’s Cancer Research Centre in Ghana
STOCKHOLM, November 25, 2021 – Elekta (EKTA-B.ST) announced today that its latest African order for Elekta Unity MR-Linac comes less than six months after the company introduced its ACCESS 2025 strategy, which includes giving more than 300 million people access to radiation therapy with the addition of 825 additional Elekta linacs in underserved markets.

In addition to the Unity system, the Eugene Gasana Jr. Foundation signed an]]></description><pubDate>Thu, 25 Nov 2021 08:00:00 GMT</pubDate></item><item><title>Interim report, May–October 2021/22</title><link>https://news.cision.com/elekta/r/interim-report--may-october-2021-22,c3460339</link><guid isPermaLink="false">cision4125373</guid><description><![CDATA[The increasing need for investments in cancer care and radiotherapy across the globe supported a gradual market recovery during the quarter. Our orders grew with double digits, and despite the continued global supply chain challenges we secured good revenue growth supported by a strong finish of the quarter. Our margins improved sequentially but were still impacted by higher logistics costs.

Gustaf Salford
President and CEO
Second quarter

  · Gross order intake amounted to SEK 4,045 M (3,627), corresponding to a 12 percent increase in constant currency
  · Net sales were SEK 3,697 M (]]></description><pubDate>Thu, 25 Nov 2021 06:30:00 GMT</pubDate></item><item><title>Invitation to the presentation of Elekta’s second quarter 2021/22</title><link>https://news.cision.com/elekta/r/invitation-to-the-presentation-of-elekta-s-second-quarter-2021-22,c3446424</link><guid isPermaLink="false">cision4107147</guid><description><![CDATA[SWEDEN, November 4, 2021 – Elekta (EKTA-B.ST) invites analysts and investors to a presentation of the second quarter 2021/22 at 10:00 a.m. CET on November 25. The interim report for the second quarter will be published at 7:30 a.m. CET on the same day.

The company’s development will be presented by Elekta’s President and CEO, Gustaf Salford, together with CFO, Johan Adebäck. After the presentation, held in English, a Q&A session will follow.

The presentation will be broadcast live on the web. It will be necessary to join the phone conference if you plan to ask questions. A recording]]></description><pubDate>Thu, 04 Nov 2021 06:30:00 GMT</pubDate></item><item><title>Award-winning abstracts confirm benefits of Elekta Unity in precision radiation therapy</title><link>https://news.cision.com/elekta/r/award-winning-abstracts-confirm-benefits-of-elekta-unity-in-precision-radiation-therapy,c3443641</link><guid isPermaLink="false">cision4103252</guid><description><![CDATA[CHICAGO, October 29, 2021 – Elekta (EKTA-B.ST) today announced the presentation of new award-winning abstracts supporting the many benefits of Elekta Unity in treating cancer patients using precision radiation therapy. The abstracts add to the growing body of data manifesting Elekta Unity’s unique capabilities, to the benefit of patients around the world.

The system is highly appreciated by leading clinics around the world and, as of today, Elekta has sold more than 100 Elekta Unity systems.

Lionel Hadjadjeba, President MR-Linac Solutions, said: “In Unity, we have developed a system]]></description><pubDate>Fri, 29 Oct 2021 14:00:00 GMT</pubDate></item><item><title>Elekta establishes a framework for sustainability-linked bonds</title><link>https://news.cision.com/elekta/r/elekta-establishes-a-framework-for-sustainability-linked-bonds,c3442936</link><guid isPermaLink="false">cision4102616</guid><description><![CDATA[Elekta AB (publ) has established a Sustainability-Linked Bond Framework. Another step in strengthening Elekta’s sustainability focus and emphasis on access to the best cancer care.
STOCKHOLM, October 29, 2021 – Elekta (EKTA-B.ST) announced today that it has established a Sustainability-Linked Bond Framework (SLB Framework) for issues of sustainability-linked bonds under its Medium Term Note Program (https://www.elekta.com/investors/funding/mtn-program/) (MTN-Program). Elekta is among the first companies in Sweden to establish this type of investment framework for bonds. This strengthens]]></description><pubDate>Fri, 29 Oct 2021 06:30:00 GMT</pubDate></item><item><title>Elekta’s Nomination Committee for the 2022 Annual General Meeting</title><link>https://news.cision.com/elekta/r/elekta-s-nomination-committee-for-the-2022-annual-general-meeting,c3440664</link><guid isPermaLink="false">cision4100638</guid><description><![CDATA[STOCKHOLM, October 28, 2021 – In accordance with the resolution passed by Elekta’s (EKTA-B.ST) Annual General Meeting on August 25, 2021, the Chairman of the Board has convened the Nomination Committee for the 2022 Annual General Meeting by contacting the company’s largest shareholders in terms of votes, in addition to the shareholder or shareholders represented by the Chairman himself. The procedure is described in detail in the notice to the 2021 Annual General Meeting.

The Nomination Committee consists of:

  · Laurent Leksell, in his capacity as Chairman of the Board of Elekta and]]></description><pubDate>Thu, 28 Oct 2021 05:30:00 GMT</pubDate></item><item><title>Elekta receives initial investment grade rating from S&amp;P Global Ratings</title><link>https://news.cision.com/elekta/r/elekta-receives-initial-investment-grade-rating-from-s-p-global-ratings,c3440528</link><guid isPermaLink="false">cision4098889</guid><description><![CDATA[STOCKHOLM, October 26, 2021 – Elekta (EKTA-B.ST) announced today that it has received an investment grade (IG) rating from S&P Global Ratings (S&P). S&P has assigned a BBB- rating to Elekta and to the Group’s senior unsecured notes, with stable outlook. S&P notes that Elekta’s rating reflects the global leading position, ability to introduce new innovative treatment solutions and the key credit strengths being low leverage and stable cash generation.

“We are very pleased to have secured an investment grade rating from S&P, which reflects our strong financial position,” stated Johan]]></description><pubDate>Tue, 26 Oct 2021 12:20:00 GMT</pubDate></item><item><title>Elekta acquires Turkish distributor to strengthen market position</title><link>https://news.cision.com/elekta/r/elekta-acquires-turkish-distributor-to-strengthen-market-position,c3408482</link><guid isPermaLink="false">cision4056506</guid><description><![CDATA[STOCKHOLM, September 2, 2021 – Elekta (EKTA-B.ST) announced today that it has acquired its long-time partner and Turkish distributor of neurosurgery solutions, Özyürek Mümessillik ve Dış Ticaret A.Ş. (Özyürek A.Ş.). The acquisition will improve Elekta’s market access in the region and strengthen its relationship with customers.

Cancer of the nervous system is one of the most common types of cancers in the world[1]. To effectively treat these tumors and other brain disorders, leading healthcare centers around the world choose Leksell Gamma Knife[®] for its accuracy and documented outcomes.]]></description><pubDate>Thu, 02 Sep 2021 05:30:00 GMT</pubDate></item><item><title>Elekta Unity MR-Linac featured in 72 abstracts at European radiation oncology congress</title><link>https://news.cision.com/elekta/r/elekta-unity-mr-linac-featured-in-72-abstracts-at-european-radiation-oncology-congress,c3406468</link><guid isPermaLink="false">cision4053290</guid><description><![CDATA[MADRID, August 31, 2021 – Elekta (EKTA-B.ST) today announced the presentation of 72 abstracts demonstrating the technical capabilities and clinical utility of the Elekta Unity MR-Linac. The research described in the abstracts was conducted at 14 leading cancer centers worldwide, reflecting the broad global adoption of the system. The abstracts were reported at the European SocieTy for Radiotherapy and Oncology (ESTRO) which took place 27-31 August in Madrid, Spain.

“The Elekta Unity data presented at ESTRO include a growing number of abstracts reporting clinical data in multiple anatomic]]></description><pubDate>Tue, 31 Aug 2021 05:30:00 GMT</pubDate></item><item><title>Elekta’s Board announces establishment of philanthropic Elekta Foundation</title><link>https://news.cision.com/elekta/r/elekta-s-board-announces-establishment-of-philanthropic-elekta-foundation,c3403323</link><guid isPermaLink="false">cision4048839</guid><description><![CDATA[Shareholders agree to support initiatives that expand access to cancer care
STOCKHOLM, August 26, 2021 – At its Annual General Meeting on August 25, Elekta’s (EKTA-B.ST) shareholders approved the Board of Directors’ proposal to establish the Elekta Foundation. The Elekta Foundation’s mission is an important part of Elekta’s environmental, social, and governance (ESG) strategy and priorities. Its mission is to initiate and support projects and programs in partnership with governments, NGOs and healthcare providers in low- and middle-income countries to improve access to cancer care.

Dr.]]></description><pubDate>Thu, 26 Aug 2021 05:30:00 GMT</pubDate></item><item><title>Report from the Annual General Meeting 2021 in Elekta</title><link>https://news.cision.com/elekta/r/report-from-the-annual-general-meeting-2021-in-elekta,c3397386</link><guid isPermaLink="false">cision4048343</guid><description><![CDATA[STOCKHOLM, August 25, 2021 – Elekta AB (publ) has held its Annual General Meeting on 25 August 2021. In light of the extraordinary situation prevailing as a result of Covid-19, the Meeting was conducted by advance postal vote, without physical attendance. A statement from the CEO and President as well as an interview with the Chairman of the Board of Directors can be found on Elekta’s website, www.elekta.com.

Documents from the Meeting with complete details concerning all resolution is also available on the website.A summary of the resolutions taken by the Meeting follows.

Accounting]]></description><pubDate>Wed, 25 Aug 2021 12:00:00 GMT</pubDate></item><item><title>Interim report, May–July 2021/22</title><link>https://news.cision.com/elekta/r/interim-report--may-july-2021-22,c3402615</link><guid isPermaLink="false">cision4047738</guid><description><![CDATA[Market recovery with short-term cost challenges

The market continued to recover with stronger demand and better access to customers particularly in more mature markets. Orders grew by double digits, when excluding Elekta’s largest order ever in the first quarter last year. Installation volumes increased and revenue grew in line with pre-pandemic levels. We are experiencing temporary headwinds to our gross margin due to increased supply-chain, logistics and service costs.
Gustaf Salford
President and CEO

First quarter

  · Gross order intake amounted to SEK 3,980 M (4,451),]]></description><pubDate>Wed, 25 Aug 2021 05:30:00 GMT</pubDate></item><item><title>Elekta to address Indonesia’s cancer care gap with direct presence</title><link>https://news.cision.com/elekta/r/elekta-to-address-indonesia-s-cancer-care-gap-with-direct-presence,c3402699</link><guid isPermaLink="false">cision4047722</guid><description><![CDATA[Fourth largest country in the world severely underserved in cancer care
STOCKHOLM – Elekta (EKTA-B.ST) announced today that is has established permanent legal entity in Indonesia’s capital, Jakarta in order to address the unmet need for high quality, modern cancer care.

Radiation therapy is a critical component in treating cancer and is considered necessary in the treatment of over half of all cancer patients[[1]]. However, according to GLOBOCAN[[2]], more than 15,000 linear accelerators are required globally to close the gap between countries with sufficient cancer resources and those]]></description><pubDate>Wed, 25 Aug 2021 05:29:00 GMT</pubDate></item><item><title>Invitation to the presentation of Elekta’s first quarter 2021/22</title><link>https://news.cision.com/elekta/r/invitation-to-the-presentation-of-elekta-s-first-quarter-2021-22,c3394439</link><guid isPermaLink="false">cision4036590</guid><description><![CDATA[SWEDEN, August 11, 2021 – Elekta (EKTA-B.ST) invites analysts and investors to a presentation of the first quarter 2021/22 at 10:00 a.m. CEST on August 25. The interim report for the first quarter will be published at 7:30 a.m. CEST on the same day.

The company’s development will be presented by Elekta’s President and CEO, Gustaf Salford, together with CFO, Johan Adebäck. After the presentation, held in English, a Q&A session will follow.

The presentation will be broadcast live on the web. It will be necessary to join the phone conference if you plan to ask questions. A recording of]]></description><pubDate>Wed, 11 Aug 2021 05:30:00 GMT</pubDate></item><item><title>GenesisCare extends U.S. brachytherapy service with 27 Elekta Flexitron treatment devices</title><link>https://news.cision.com/elekta/r/genesiscare-extends-u-s--brachytherapy-service-with-27-elekta-flexitron-treatment-devices,c3388776</link><guid isPermaLink="false">cision4029385</guid><description><![CDATA[ATLANTA, July 23, 2021 – Elekta (EKTA-B.ST) announced today that GenesisCare (https://www.genesiscare.com/), a leading global provider of integrated cancer care, has ordered 27 Flexitron[®] brachytherapy afterloader systems, including service agreements. The cancer treatment devices will allow GenesisCare to continue to invest in the latest world-class technology while providing access to high-quality care to their patients throughout their U.S. centers.

“With Brachytherapy an essential part of the care pathway for many cancer patients, GenesisCare offers this treatment modality across]]></description><pubDate>Fri, 23 Jul 2021 12:00:00 GMT</pubDate></item><item><title>Data from 14 leading cancer centers presented at AAPM highlight global adoption of Elekta Unity MR-Linac</title><link>https://news.cision.com/elekta/r/data-from-14-leading-cancer-centers-presented-at-aapm-highlight-global-adoption-of-elekta-unity-mr-l,c3388327</link><guid isPermaLink="false">cision4029109</guid><description><![CDATA[Presentation of 36 abstracts underscore the potential of Elekta Unity to advance precision radiation medicine
ATLANTA, July 23, 2021 – Elekta (EKTA-B.ST) today announced the presentation of 36 abstracts demonstrating the technical capabilities and clinical utility of the Elekta Unity MR-Linac. The research described in the abstracts was conducted at 14 leading cancer centers in North America, Europe, Asia and Australia, reflecting the broad global adoption of the system. The abstracts are being reported at the 63[rd] Annual Meeting & Exhibition of the American Association of Physicists in]]></description><pubDate>Fri, 23 Jul 2021 05:30:00 GMT</pubDate></item><item><title>Notice to the Annual General Meeting of Elekta AB (publ)</title><link>https://news.cision.com/elekta/r/notice-to-the-annual-general-meeting-of-elekta-ab--publ-,c3393712</link><guid isPermaLink="false">cision4027875</guid><description><![CDATA[The shareholders of Elekta AB (publ), reg. no 556170–4015 are hereby convened to the Annual General Meeting to be held on Wednesday 25 August 2021.
Due to the coronavirus pandemic, the Board of Directors has decided that the Meeting should be conducted without the physical presence of shareholders, representatives or third parties and that the shareholders before the meeting should be able to exercise their voting rights only by voting in advance, so-called postal voting. Information on the resolutions passed at the Meeting will be published on Wednesday 25 August 2021, as soon as the result]]></description><pubDate>Wed, 21 Jul 2021 05:30:00 GMT</pubDate></item><item><title>Elekta's Annual Report for 2020/21 available</title><link>https://news.cision.com/elekta/r/elekta-s-annual-report-for-2020-21-available,c3382787</link><guid isPermaLink="false">cision4021666</guid><description><![CDATA[STOCKHOLM – Elekta’s (EKTA-B.ST) Annual Report for 2020/21 can now be downloaded from the investor section on the company’s website, www.elekta.com/investors, and is also enclosed with this press release.

In addition to Elekta’s audited statutory annual report, the report also contains the sustainability report, based on GRI Standards, the corporate governance report, and Elekta’s first remuneration report.

“We managed to increase orders, gaining market shares, and grow the installed base in a pandemic affected market, giving more cancer patients access to radiotherapy. The successful]]></description><pubDate>Fri, 09 Jul 2021 09:00:00 GMT</pubDate></item></channel></rss>